Ask an ABTA Researcher
The ABTA receives so many great questions from patients, caregivers and supporters across the country, that we thought it would be great to share the questions we get and, more importantly, the answers.
Q: Are generic drugs equally as effective as the name brand medicine?
Answer provided by Maria J. Sambade, PhD. Dr. Sambade is a research associate in Lineberger Comprehensive Cancer Center working with Dr. Carey Anders, studying how brain metastases of breast, lung and melanoma cancers might be made more sensitive to radiation therapy. Click here to read Dr. Sambade's full answer.
We would love to hear from you. If you have a question you would like to submit, click here.
Registration is Open for the 2014 Patient and Family Conference
Join us for the ABTA's 2014 conference, "Providing and Pursuing Answers: Advances in Research, Treatment and Care," taking place July 25-26 in Chicago.
Meet and speak with leading neuro-oncology physicians and researchers, allied health care professionals and other patients and caregivers. Register at www.braintumorconference.org.
ABTA-funded Research Moves Further into Development
Tocagen Inc., has announced that their investigational therapy using Toca 511 & Toca FC, whose development was partially supported by an ABTA Clinical Research Grant, has moved forward into a new clinical trial. In this trial, the drug will be delivered intravenously (IV) prior to surgery, as well as into the tumor directly. (Previous trials delivered the drug directly into the tumor, without the pre-surgical IV dosing.) The treatment is being offered to patients with recurrent high grade glioma, including glioblastoma, who meet specific eligibility guidelines. Click here to read more about the Tocagen trial.
Get Ready to Raise Awareness
It's only early April, but May - Brain Tumor Awareness Month - will be here before we know it. Be sure to keep an eye out for an email about how you can do some new and exciting things to raise awareness for brain tumors and the ABTA this May. Get a head start and order gray wristbands from the ABTA store to show your support of our mission.
Changes Come to NCI Clinical Trial Standards
Based on a report from the Institute of Medicine (IOM), the National Cancer Institute (NCI), is making changes to keep pace with advances in the scientific understanding of cancer. A new National Clinical Trials Network (NCTN) will bring together larger groups of investigators and distribute resources in a more effective way to improve the speed and efficiency of clinical trials. In addition, at the local level, NCI will be combining several existing programs into an NCI Community Oncology Research Program (NCORP), that allows community-based care programs to benefit from resources available through the NCTN. To read more about these changes, click here.
Genetic Mutations Found in Craniopharyngiomas
While much genetic research focuses on malignant gliomas, ABTA 2012 Fellowship recipient Priscilla Brastianos, MD, along with ABTA Scientific Advisor, Edward Laws, Jr., MD, and a team of researchers recently identified two gene mutations linked to craniopharyngiomas. The research team’s study revealed BRAF mutations in 95% of papillary craniopharyngiomas (36 of 39 tumors) and CTNNB1 mutations in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The discoveries are important because the genetic changes offer researchers the opportunity to develop molecularly-guided therapies targeted against these mutations. The study was partially funded by the ABTA, and recently published study in Nature Genetics. Read the article here.
Interested in learning more about craniopharyngioma? The ABTA will offer a webinar on this topic May 6, 2014. Click here to register.
Tuesday, May 6 at 1 p.m. – Treatment of Craniopharyngiomas: An Updated on Current Trends in Surgical, Medical and Radiation Therapy.
Join Kevin Lillehei, MD, of University of Colorado Hospital, as he discussed the clinical presentation of craniopharyngioma, the associated pathological features, their management and current trends in therapy. Click here to RSVP.
Missed a webinar? You can watch it anytime.
All of the ABTA's past webinars are online at the Anytime Learning section of www.abta.org.
First BT5K Starts an Event Season of Breakthroughs
The Tampa Bay BT5K took place on March 29, and was an enormous success. More than $80,000 was raised thanks to over 670 participants who came out to show support of the ABTA. Click here to see photos from the event.
This event is the first of many thorughout the spring season. Visit www.bt5k.org to find an event near you!
Team "Babes Against Brain Cancer" at the Tampa Bay BT5K
Run with Heidi this October
The ABTA still has guaranteed entries for the 2014 Bank of America Chicago Marathon. You can run with supporters like Heidi Tyrrell, a brain tumor survivor and member of Team Breakthrough. Heidi will be running 26.2 miles just days before her one year anniversary of brain surgery. "This is my time to give back and raise awareness about brain tumors," Heidi said. "I'll be running my heart out and showing cancer that a brain tumor will not stop me, but rather make me stronger and more determined."
Visit www.abtateambreakthrough.org to learn about how you can join Heidi as part of Team Breakthrough this year!